Flaxseed Oil
Overview
Flaxseed oil is a rich source of alpha-linolenic acid (ALA), an omega-3 fatty acid. Omega-3 fatty acids (n-3) constitute one of two major families of polyunsaturated fatty acids, the other family being omega-6 (n-6). ALA is the parent substance of the n-3 fatty acid family. Linoleic acid is the parent substance for the n-6 fatty acid family. These two families have very different biochemical roles in the body. ALA is an essential fatty acid and is necessary for the normal function of all tissues. Through a series of steps, it is metabolized to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and prostaglandins in the body. Prostaglandins are hormone-like compounds that help regulate blood pressure, blood clotting, heart rate, vascular dilation, lipolysis, and immune response.
American diets are typically high in n-6 fatty acids and low in n-3 fatty acids. The average diet supplies only 0.15 g of n-3 fatty acids per day. A high ratio of n-6:n-3 fatty acid may encourage production of proinflammatory metabolites (arachidonic acid, prostaglandin E1, and prostaglandin E2) and negatively affect the body's response to disease. Changing the intake of dietary fatty acids may modify the body's response to disease, injury, and infection. Clinical trials indicate that supplementation with n-3 fatty acids from plants such as flaxseed can encourage production of the anti-inflammatory metabolites and inhibit the production of pro-inflammatory metabolites.
ALA is used as a source of energy by the body and partly as a precursor of the metabolites. Most studies indicate that a certain amount of ALA is converted to EPA in the body but conversion to DHA is limited. Results of one study showed that with a diet high in saturated fat conversion to EPA and DHA is approximately 6% and 3.8%, respectively. With a diet rich in n-6 polyunsaturated fatty acids, conversion is reduced by 40% to 50%. Flaxseed oil raises tissue EPA levels comparably to fish oil when dietary linoleic acid is restricted. In one study, the degree of conversion was proportional to a weekly portion (50 to 100 g) of fatty fish depending on the fat content of the fish. In some instances, ALA may be an effective alternative to fish oil supplements. However, a high ratio of ALA:linoleic acid may be necessary to produce the effects demonstrated after ingesting fish oils.
Deficiencies in essential fatty acid can reduce both primary and secondary immune responses and modify the inflammatory response in animals. Symptoms associated with a deficiency in n-3 fatty acids include neurological changes (parasthesias, weakness, pain in the legs, inability to walk) and impaired vision.
Dietary Sources
Ground flaxseed or flaxmeal
Constituents/Composition
Flaxseed contains 55% to 65% essential fatty acids, beta-carotene, and mixed carotenoids. Some processors add vitamin E to increase the oil's stability and shelf life.
Commercial Preparations
Therapeutic Uses
Dosage Ranges and Duration of Administration
One to 3 tsp. liquid flaxseed oil per day, or 3,000 mg (capsules) bid, as a starting dose is most recommended.
Dosage for disease prevention and treatment will vary depending on fatty acid content of the diet, individual body physiology (ALA conversion to EPA), and the type of disorder.
Side Effects/Toxicology
There are no side effects or toxicity associated with increased intake of flaxseed oil.
Warnings/Contraindications/Precautions
Flaxseed oil can add additional calories and fat to the diet if there is not a compensatory reduction in other fats.
Interactions
No clinically significant interactions between flaxseed oil and conventional medications are known to have been reported in the literature to date, including the German Commission E monograph (Blumenthal 1998). Although clinical relevance is unknown, flaxseed oil may interfere with the absorption of certain medications; therefore, ingestion of flaxseed oil several hours before or after other herbs or medications may be warranted. Please see monograph on Alpha Linolenic Acid for additional information regarding that active ingredient.
References
Allman-Farinelli MA, Hall D, Kingham K, Pang D, Petocz P, Favaloro EJ. Comparison of the effects of two low fat diets with different alpha-linolenic acid ratios on coagulation and fibrinolysis. Atherosclerosis. 1999;142:159-168.
Bierenbuam ML, Reichstein R, Watkins TR. Reducing atherogenic risk in hyperlipemic humans with flaxseed supplementation: a preliminary report. J Am Coll Nutr. 1993;12:501-504.
Blumenthal M, ed. The Complete German Commission E Monographs Therapeutic Guide to Herbal Medicines. Boston: Integrative Medicine Communications; 1998:132.
Clark WF, Parbtani A, Hugg MW, et al. Flaxseed: a potential treatment of lupus nephritis. Kidney Int. 1995;48:475-480.
Cunnane SC, Ganguli S, Menard C, et al. High alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr. 1993;69:443-453.
Cunnane SC, Hamadeh MJ, Liede AC, Thompson LU, Wolever TM, Jenkins DJ. Nutritional attributes of traditional flaxseed in healthy-young adults. Am J Clin Nutr. 1995;61:62-68.
Das UN, Madhavi N, Sravan KG, Padma M, Sangeetha P. Can tumor cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids. 1998;58:39-54.
Dox IG, Melloni BJ, Eisner GM. The HarperCollins Illustrated Medical Dictionary. New York, NY: HarperCollins Publishers; 1993.
Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res. 1998;68:159-173.
Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. May 1997;65(suppl 5):1645S-1654S.
Heller A, Koch T, Schmeck J, Van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55:487-496.
Ingram AJ, Parbtani A, Clark WF, et al. Effects of flax oil diets in a rat-5/6 renal ablation model. Am J Kidney Dis. 1995;25:320-329.
Kaminskas A, Levaciov, Lupinovic V, Kuchinskene Z. The effect of linseed oil on the fatty acid composition of blood plasma low- and very low-density lipoproteins and cholesterol in diabetics [in Russian]. Vopr Pitan. 1992;5-6:13-14.
Leece EA, Allman MA. The relationships between dietary alpha-linolenic: linoleic acid and rat platelet eicosapentaenoic and arachidonic acids. Br J Nutr. 1996;76:447-452.
Mantzioris E, James MJ, Gibson RA, Cleland LG. Differences exist in the relationships between dietary linoleic and alpha-linolenic acids and their respective long-chain metabolites. Am J Clin Nutr. 1995;61:320-324.
Mayser P, Mrowietz U, Arenberger P, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998;38:539-547.
Murray MT, Pizzorno JE. Encyclopedia of Natural Medicine. 2nd ed. Rocklin, Calif: Prima Publishing; 1998.
Nestel PJ, et al. Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol. 1997;17:1163-1170.
Norman AW, Litwack G. Hormones. Orlando, Fla: Academic Press, Inc; 1987.
Orten JM, Neuhaus OW, eds. Human Biochemistry. 10th ed. St. Louis, Mo: The C.V. Mosby Company; 1982.
Prasad K. Dietary flaxseed in prevention of hypercholesterolemic atherosclerosis. Atherosclerosis. 1997;132:69-76.
Shils ME, Olson JA, Shike M, eds. Modern Nutrition in Health and Disease. 8th ed. Media, Pa: Williams and Wilkins Co; 1994:1.
Schmidt MA. Smart Fats: How Dietary Fats and Oils Affect Mental, Physical and Emotional Intelligence. Berkeley, Calif: Frog, Ltd; 1997.
Valsta LM, Salminen I, Aro A, Mutanen M. Alpha-linolenic acid in rapeseed oil partly compensates for the effect of fish restriction on plasma long chain n-3 fatty acids. Eur J Clin Nutr. 1996;50:229-235.
Copyright © 2000 Integrative Medicine Communications